Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D09YRA
|
|||
| Former ID |
DNCL003730
|
|||
| Drug Name |
SSTarbaclofen
|
|||
| Indication | Autism spectrum disorder [ICD-11: 6A02; ICD-10: F84.0] | Phase 2 | [1], [2] | |
| Fragile X syndrome [ICD-11: LD55; ICD-10: Q99.2] | Phase 2 | [1], [2] | ||
| Company |
Seaside Therapeutics; Roche
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Gamma-aminobutyric acid B receptor (GABBR) | Target Info | Modulator | [3] |
| KEGG Pathway | cAMP signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| GABAergic synapse | ||||
| Estrogen signaling pathway | ||||
| Morphine addiction | ||||
| Reactome | Activation of G protein gated Potassium channels | |||
| G alpha (i) signalling events | ||||
| Class C/3 (Metabotropic glutamate/pheromone receptors) | ||||
| Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits | ||||
| WikiPathways | GPCRs, Class C Metabotropic glutamate, pheromone | |||
| Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell | ||||
| Potassium Channels | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01288716) Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders. U.S. National Institutes of Health. | |||
| REF 2 | Effects of STX209 (Arbaclofen) on Neurobehavioral Function in Children and Adults with Fragile X Syndrome: A Randomized, Controlled, Phase 2 Trial. Science Translational Medicine Vol 4, Issue 152 19 September 2012. | |||
| REF 3 | Reversal of disease-related pathologies in the fragile X mouse model by selective activation of GABAB receptors with arbaclofen. Sci Transl Med. 2012 Sep 19;4(152):152ra128. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.